CCCG方案治疗T-NHL-Ⅲ Ⅳ期的临床观察  

The Clinical Study on the Treatment of Ⅲ、Ⅳ Stage T-NHL Using CCCG Regimen

作　　者：李璋琳[1] 陈鸿骏[1] 闫杰[1] 曹嫣娜[1] 

机构地区：[1]天津医科大学附属肿瘤医院儿科,天津市300060

出　　处：《中国肿瘤临床》2005年第14期814-816,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:观察中国儿童肿瘤协作组(CCCG)化疗方案在治疗晚期恶性淋巴瘤(T-NHL)的疗效。方法:1998年9月至2002年9月收治的Ⅲ、Ⅳ期T-NHL24例,根据适应证要求、治疗前检查及疗效评估标准,11例纳入本方案治疗。结果:11例患者中,完成化疗并持续缓解7例,CR最长者58个月;死亡4例:2例分别持续缓解16个月和24个月最终死于肿瘤复发;1例死于药物毒性;1例死于进展。结论:CCCG方案能提高晚期T-NHL的生存率,延长生存期,但化疗药物不良反应和骨髓抑制严重。Objective： To observe treatment effetiveness of Ⅲ and Ⅳ stage T-NHL using CCCG regimen. Methods： From Sept 1998 to Sept 2002, 24 cases with Ⅲ and Ⅳ stage T-NHL were admitted in the hospital. According indications, examination before treatment and assessment standard about effectiveness, 11 cases were brought into this CCCG regimen group. Results： Continuous remission occurred in seven cases and the longest time of CR was 58 months; the remaining four were dead （among which two have kept continuous remission for 15 and 24 months respectively and they died of recurrence; one died of drug toxicity and one died of progression）. Conclusion： CCCG regimen can improve survival rate and prolong survival time. Because of drug toxicity and serious myelosuppression, it is difficult to be generalized widespreadly in hospitals at lower level.

关 键 词：CCCG方案 晚期恶性淋巴瘤 Ⅲ期 Ⅳ期 

分 类 号：R733.1[医药卫生—肿瘤]